Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A bitopic mTORC inhibitor reverses phenotypes in a tuberous sclerosis complex model.

Scientific reports - 1 Jul 2025

Mukherjee Sulagna, Wolan Matthew J, Scott Mary K, Riley Victoria A, Sokolov Aidan M, Feliciano David M

Abstract excerpt

Neural stem cells (NSCs) of the ventricular-subventricular zone (V-SVZ) generate diverse cell types including striatal glia during the neonatal period. NSC progeny uncouple stem cell-related mRNA transcripts from being translated during differentiation. We previously demonstrated that Tsc2 inactivation, which occurs in the neurodevelopmental disorder Tuberous Sclerosis Complex (TSC), prevents this from happening....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Disease Models, Animal
Share to Mechanistic Target of Rapamycin Complex 1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neural Stem Cells

Share to Phenotype

Share to Sirolimus

Share to Tuberous Sclerosis

Share to Tuberous Sclerosis Complex 2 Protein

Source

Open in PubMed Open full text

Identifiers

PMID: 40594897
DOI: 10.1038/s41598-025-08345-z
PMCID: PMC12218406

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A bitopic mTORC inhibitor reverses phenotypes in a tuberous sclerosis complex model.PMID 40594897Read ↗

Loss of Tsc2 in Neonatal V-SVZ Neural Stem Cells Causes Rare Malformations Tsc2 Mutation Causes Rare MalformationsSemantic proximity Read ↗

Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function.Semantic proximity Read ↗

Tsc2 coordinates neuroprogenitor differentiationSemantic proximity Read ↗

TSC patient-derived isogenic neural progenitor cells reveal altered early neurodevelopmental phenotypes and rapamycin-induced MNK-eIF4E signaling.Semantic proximity Read ↗

Genetic Etiologies, Diagnosis, and Treatment of Tuberous Sclerosis ComplexSemantic proximity Read ↗

Pathological Findings of a Subependymal Giant Cell Astrocytoma Following Treatment With Rapamycin.Semantic proximity Read ↗

Potential of mTOR inhibitors for the treatment of subependymal giant cell astrocytomas in tuberous sclerosis complexSemantic proximity Read ↗

Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation.Semantic proximity Read ↗

Sustained activation of mTOR pathway in embryonic neural stem cells leads to development of tuberous sclerosis complex-associated lesions.Semantic proximity Read ↗

Pharmacological treatment strategies for subependymal giant cell astrocytoma (SEGA).Semantic proximity Read ↗

Developmental Characterization of Neuronal Migration Anomalies and Axon Proliferation in mTOR pathway-associated Malformations of Cortical DevelopmentSemantic proximity Read ↗

Translatome analysis of tuberous sclerosis complex 1 patient-derived neural progenitor cells reveals rapamycin-dependent and independent alterationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.